Treatment of acute myeloid leukemia (AML): Recent results and new directions1
Abstract
#No Abstract#
Hann IM., Stevens RF, Goldstone AH, et al. Random- ized comparison of DAT versus ADE as induction che- motherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council’s 10th AML Trial (MRC AML10). Blood 1997;89:2311-8
Burnett AK, Goldstone AH, Stevens RM, et al. Ran- domised comparison of addition of autologous bone- marrow transplantation to intensive chemotherapy of acute myeloid leukaemia in first remission: results of MRC AML10 trial. The Lancet 1998;351:700-8
Mandelli F, Vegna ML, Avvisati G, et al. A random- ized study of the efficacy of postconsolidation therapy in adult acute nonlymphocytic leukemia: a report of the Ital- ian Cooperative Group GIMEMA. Annals of Hematol- ogy 1992;64:166-72
Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. New England Jour- nal of Medicine 1998;339:1649-56
Rai KR, Hollannd JF, Glidewell OJ, et al. Treatment of acute myeloid leukemia: A study by Cancer and Leu- kemia Group B. Blood 1981;58:1203-12
Yates J, Glidewell O, Wiernik P, et al. Cytosine ara- binoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: A CALGB study. Blood 1982;60:454-62
Büchner T, Urbanitz D, Hiddemann W, et al. Intensi- fied Induction and Consolidation with or without mainte- nance chemotherapy for acute myeloid leukemia (AML): Two multicenter studies of the German AML Coopera- tive Group. Journal of Clinical Oncology 1985;3:1583-9
Rees JKH, Gray RG, Swirsky D, Hayhoe FGJ. Prin- cipal results of the Medical Research Council’s 8th acute myeloid leukaemia trial. The Lancet 1986;332:1236
Hayat M, Jehn U, Willemze R, et al. A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia. Cancer 1986;58:617-23
Zittoun R, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. New England Journal of Medicine 1995;332:217-223
Preisler H, Davis RB, Kirshner J, et al. Comparison of three remission induction regimens and two postinduc- tion strategies for the treatment of acute nonlymphocytic leukemia: A Cancer and Leukemia Group B Study. Blood 1987;69:1441-9
Hansen OP, Pedersen- Bjergaard J, Ellegaard J, et al. Aclarubicin plus cytosine arabinoside versus daunorubi- cin plus cytosine arabinoside in previously untreated pa- tients with acute myeloid leukemia: a Danish National Phase III Trial. Leukemia 1991;5:510-6
Dillman RO, Davis RB, Green MR, et al. A compara- tive study of two different doses of cytarabine for acute myeloid leukemia: A phase III trial of Cancer and Leu- kemia Group B. Blood 1991;78:2520-6
Cassileth PA, Lynch E, Hines JD, et al. Varying in- tensity of postremission therapy in acute myeloid leuke- mia. Blood 1992;79:1924-30
Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. New England Journal of Medicine 1994;6:896- 942
Bishop JF, Matthews JP, Young GA, et al. A random- ized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996;87:1710-7
Weick JK, Kopecky KJ, Appelbaum FR, et al. A ran- domized investigation of high-dose versus standard dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A South- west Oncology Study Group. Blood 1996;88:2841-51
Büchner T, Hiddemann W, Wörmann B, et al. Double induction strategy for acute myeloid leukemia: The effect of high-dose cytarabine with mitoxantrone instead of standard- dose cytarabine with daunorubicin and 6- thioguanine. A randomized trial by the German AML Cooperative Group. Blood 1999;93:4116-24
Büchner T, Hiddemann W, Berdel W, et al. 6- Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induc- tion, TAD for consolidation, and either prolonged main- tenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de- novo acute myeloid leukemia (AML): A randomized trial by the German AML Cooperative Group. Journal of Clinical Oncology 2003;21:4496-4504
Löwenberg B, van Putten W, Theobald M, et al. Ef- fect of priming with granulocyte colony- stimulating fac- tor on the outcome of chemotherapy for acute myeloid leukemia. New England Journal of Medicine 2003;349:743-752
Rowe JM, Andersen JW, Mazza JJ, et al. A random- ized placebo- controlled phase III study of granulocyte- macrophage colony- stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leuke- mia: A study of the Eastern Cooperative Oncology Group (E1490). Blood 1995;86:457-62
Witz F, Sadoun A, Perrin MC, et al. A placebo- con- trolled study of recombinant human granulocyte- macrophage colony- stimulating factor administered dur- ing and after induction treatment for de novo acute mye- logenous leukemia in elderly patients. Blood 1998;91:2722-30
Goldstone AH, Burnett AK, Wheatley K, et al. At- tempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML 11 trial. Blood 2001;98:1302-11
Anderson J, Kopecky K, Willmann C, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxan- trone and etoposide compared to cytarabine and daun- orubicin: A Southwest Oncology Group study. Blood 2002;100:3869-3876
Stone RM, Berg TB, George SL, et al. Granulocyte- macrophage colony-stimulating factor after initial che- motherapy for elderly patients with primary acute mye- logenous leukemia. New England Journal of Medicine 1995;332:1671-7
Stone RM, Berg DT, George SL, et al. Postremission therapy in older patients with de novo acute myeloid leu- kemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytara- bine. Blood 2001;98:548-53
Büchner T, Hiddemann W, Wörmann B, et al. Daun- orubicin 60 instead of 30 mg/sqm improves response and survival in elderly patients with AML. Blood 1997:90 (Suppl 1):583a
Dombret H, Chastang C, Fenaux P, et al. A controlled study of recombinant human granulocyte colony- stimulating factor in elderly patients after treatment for acute myelogenous leukemia. New England Journal of Medicine 1995;332:1678-83
Rees JKH, Gray RG, Weathley K. Dose intensifica- tion in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council’s AML9 study. British Journal of Haematology 1996;94:89-98
Bishop JF, Lowenthal RM, Joshua D, et al. Etoposide in acute nonlymphocytic leukemia. Blood 1990;75:27-32
Löwenberg B, Suciu S, Archimbaud E, et al. Mi- toxantrone versus daunorubicin in induction- consolidation chemotherapy – The value of low-dose cy- tarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: Final report of the Leukemia Cooperative Group of the European Organisation for the Research and Treatment of Cancer and the Dutch-Belgian Hemato- Oncology Cooperative Hovon Group randomized phase III study AML-9. Journal of Clinical Oncology 1998;16:872-81
Rowe J, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004;103:479-485
Büchner T, Berdel WE, Wörmann B, et al. Treatment of older patients with AML. Critical Reviews in Oncol- ogy/ Hematology 2005 (in press)
Huang M, Ye Y, Chen S, et al. Use of all- trans reti- noic acid in the treatment of acute promyelocytic leuke- mia. Blood 1988; 72:567-572
Avvisati G, Lo Coco F, Diverio D, et al. AIDA ( All- trans Retinoic Acid + Idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malat- tie Ematologiche Maligne Dell’ Adulto (GIMEMA) pilot study. Blood 1996;8:1390-1398
Sanz MA, Martin G, Rayon C, et al. A modified AIDA protocol with anthracycline- based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RAR α-positive acute promye- locytic leukemia. Blood 1999;94:3015-3021
Lengfelder E, Reichert A, Schoch C, et al. Double induction strategy including high dose cytarabine in combination with all- trans retinoic acid: effects in pa- tients with newly diagnosed acute promyelocytic leuke- mia. Leukemia 2000; 14:1362-1370
Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic triox- ide (As203) in the treatment of acute promyelocytic leu- kemia (APL). II Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1992;79:543-553
Gavamzadeh A, Alimoghaddam, K, Aghdami, N, Treatment of acute promyelocytic leukemia by arsenic trioxide. Proc. ASCO 2003;22:568
Shen ZX, Shi ZZ, Fang J, All- trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. PNAS 2004;101:5328-5335
Mesters R, Padró T, Bieker R, et al. Stable remission after administration of the receptor tyrosine kinase inhibi- tor SU5416 in a patient with refractory acute myeloid leukemia. Blood 2001;98:241-243
Sievers EL, Larson RA, Stadtmauer EA, et al. Effi- cacy and safety of Gemtuzumab Ozogamicin in patients with CD33-positive acute myeloid leukemia in first re- lapse. Journal of Clinical Oncology 2001;19:3244-3254
Nabhan C, Rundhaugen LM, Riley MB, et al. Phase III pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older. Leukemia Research 2005; 29:53-57
Baer MR, George SL, Dodge RK, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previ- ously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B study 9720. Blood 2002;100:1224-1232
Kolitz JE, George SL, Dodge RK, et al. Dose escala- tion studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of cancer and leukemia Group B study 9621. Journal of Clinical Oncology 2004;22:4290-4301
Büchner T, Berdel WE, Hiddemann W. Priming with granulocyte colony stimulating factor- relation to high- dose cytarabine in acute myeloid leukemia. New England Journal of Medicine 2004;350:2215-16 (letter)
Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to- treat analysis of the EORTC/GIMEMA AML-10 trial. Blood 2003;102:1232- 1240
| Files | ||
| Issue | Vol 2, No 1 (2005) | |
| Section | Articles | |
| Keywords | ||
| #No Keywords# | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
